How did ATAI's revenue and expenses shift in Q4 2024?

**ATAI Life Sciences N.V. experienced a significant shift in its revenue and expenses during Q4 2024.** Here's a detailed analysis:

1. **Revenue Shift**:
- ATAI's license revenue for Q3 2024 was $40,000, compared to $87,000 in Q3 2023.
- For the nine months ended September 30, 2024, license revenue was $313,000, compared to $296,000 in the same period of 2023.
2. **Expense Shift**:
- Total operating expenses for Q3 2024 were $22.642 million, compared to $26.921 million in Q3 2023.
- For the nine months ended September 30, 2024, total operating expenses were $72.739 million, compared to $92.206 million in the same period of 2023.
3. **Net Income (Loss) Shift**:
- The net loss for Q3 2024 was $26.311 million, a significant decrease from the net income of $43.371 million in Q3 2023.
- For the nine months ended September 30, 2024, the net loss was $111.058 million, compared to a net loss of $24.753 million in the same period of 2023.
- The net income (loss) attributable to ATAI Life Sciences N.V. stockholders for Q3 2024 was $26.286 million, down from $44.244 million in Q3 2023.
- For the nine months ended September 30, 2024, the net income (loss) attributable to stockholders was $110.311 million, compared to $21.932 million in the same period of 2023.
4. **Earnings Per Share Shift**:
- The net income (loss) per share attributable to ATAI Life Sciences N.V. stockholders was $0.16 for Q3 2024, down from $0.28 in Q3 2023.

In conclusion, ATAI Life Sciences N.V. saw a decrease in revenue and an increase in expenses during Q4 2024, leading to a significant net loss. The company's focus on clinical trials and strategic acquisitions, such as the one with IntelGenx, suggests a commitment to long-term growth and innovation in the biopharmaceutical sector.